Navigation Links
Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio
Date:9/9/2009

STOCKHOLM, September 9 /PRNewswire/ -- Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

"This is a new initiative from Karolinska Development as part of our overall strategy to maximize value appreciation within our portfolio," stated Conny Bogentoft, CEO of Karolinska Development. "We have an exciting group of technologies in this area and we expect the new corporate structure to both reduce costs and speed up development times. It also offers considerable advantages when seeking exit opportunities. Pergamum will be able to represent several or all of the development projects when discussing sales or licensing opportunities with pharma companies. We are not aware of any other similar situation within the industry," added Dr Bogentoft.

Pergamum's development projects currently cover improved wound healing and reduced scar formation, healing hard-to-heal-wounds, the prevention of bacterial and fungal infections, atopic dermatitis and infected wounds and burns.

Magnus Precht, CEO of Pergamum AB, said, "There is a good balance across the business units and we already have three projects undergoing clinical trials. What makes Pergamum different is that we provide each of our individual businesses with access to technical skills and key competencies in an extremely resource-efficient way. This is something that other companies at similar stages of development simply cannot do. In addition, by focusing on related fields we are able to continually acquire and share specialist knowledge that will benefit development over the long term."

Pergamum CEO Magnus Precht will present Pergamum at the Rodman & Renshaw Annual Global Investment Conference in New York September 9-11, 2009 and will be available for one-on-one meetings with investors and potential partners during the conference.

Pergamum's other two owners are Ostersjostiftelsen (The Foundation for Baltic and East European Studies) and Midroc New Technology.

About Karolinska Development:

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development

AB is a new type of company focused on filling the innovation gap within the pharmaceutical industry. Using a unique, highly cost-effective model Karolinska Development commercializes internationally renowned life science innovations, helping to deliver the medical products of the future.

    For more information please contact:

    Conny Bogentoft, CEO, Karolinska Development AB
    Cell phone +46-70-668-61-43
    info@karolinskadevelopment.com
   http://www.karolinskadevelopment.com

    Magnus Precht, CEO, Pergamum AB
    European mobile phone: +46-73-515-7450
    US cell phone: +1-817-312-7277
    magnus.precht@pergamum.com
   http://www.pergamum.com



'/>"/>
SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Karolinska Institutet Awards Honorary Degree to Feinstein Institute CEO Kevin J. Tracey, MD
2. Karolinska Development Invests in EvoStem Finland Oy
3. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
4. The Feinstein to collaborate with Swedens Karolinska Institute
5. 3 new honorary doctors at Karolinska Institutet
6. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
7. Special Autism Issue Published by the College of Optometrists in Vision Development
8. Cepheid Announces Accelerated Development of Flu A Panel Test
9. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
10. Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine
11. Founder of Curidium Launches Elixior, an Advisory Company Focused on the Development and Growth of Innovative Personalized Medicine Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... Source Vitál Apothecary, a skin and body care company dedicated to ... had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference ... the nutritional, sports and health industries a chance to meet in private sessions with ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an ... life, announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... States, which allows it to provide its products to all clients at reasonable prices. ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: